ISSN: 1859 - 2872
Relationship between EGFR mutations and risk of brain metastase in non-small lung cancer patients: The result from a prospective cohort study
Main Article Content
Keywords
EGFR mutation, non-small cell lung cancer metastase brain
Abstract
Objetive: To evaluate the relationship between EGFR mutations and risk of brain metastasis in non-small cell lung cancer patients (NSCLC). Subject and method: A prospective cohort study and follow-up 213 NSCLC patients stage I - IIIB, who were examined EGFR mutations in the period of 6 years, from 2014 to 2020. The risk factors were analyzed mutivariate by logistic. Result: There was 41.3% of patients with metastasis, in which, brain metastase acounted for 22.7%. The ratio of EGFR mutations were 27.2%. 37.5% brain metastase had EGFR mutations, OR = 2.89 (CI 95%: 1.011 - 8.270), p=0.048). 55.6% brain metastase patients had L858R of exon 21 was trend to higher than deletion mutations in exon 19, but this difference was not statistically significant (p>0.05). There were not the other factors relate to brain metastasis. Conclusion: EGFR mutations is a factor that increases the risk of brain metastasis in patients with non-small cell lung cancer.
Article Details
References
Fred RH, Giorgio VS, James LM et al (2017) Lung cancer: Current therapies and new targeted treatments. Lancet 389: 299-311.
2. NCCN Guideline Insights (2020) Non-small cell lung cancer. Version 3.2020, feature updates to the NCCN Guidelines.
3. Masaki H, Sun-Jin K, Isaiah JF et al (2014) The molecular biology of lung cancer brain metastasis: An overview of curent comprehensions and future perspectives. J.Med.Invest 61: 241-253.
4. Mao-hua Z, Hong-tao S, Ji-guang X et al (2016) Combining whole-brain radiotherapy with Gefitinib/Erlotinib for brain metastase from non-small cell lung cancer: A meta-analysis. BioMed Research International Volume 2016, Article ID 5807346.
5. Naoto A, Tsuneo S, Kazuhito M et al (2018) Comparison of the efficacies of the first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small cell lung cancer harboring EGFR mutations. BMC cancer 18: 1012.
6. Paz-Ares L, Tan EH, O’Byrne K et al (2017) Afatinib versus gefititnib in patients with EGFR mutation-positive advanced non-small cell lung cancer: overall survival data from the phase IIb LUX-LUNG 7 trial. Annals of Oncology 28: 270-277.
7. Soria JC, Ohe Y, Reungwetwattana T et al (2018) Osimetinib in Untreated EGFR-Mutated Advanced non-small cell lung cancer. The New England Journal of Medicine 378(2): 113-125.
8. Sally CM Lau, Ullas B, Tony SK Mok et al (2019) Dacomitinib in the management of advanced non-small cell lung cancer. Drugs 79(8): 823-831.
9. Fred H, Alex DC, David A et al (2016) EGFR mutation status on brain metastases from non-small cell lung cancer. Lung cancer 96: 101-107.
10. Vijaya RB, Sanyo D’Souza P, Lynette MS et al (2017) Pidermal Growth Factor Receptor mutations status and brain metastases in non-small cell lung cancer. Journal of Global Oncology 3(3): 208-217.
11. Devarati M, Yu-Hui C, Richard L et al (2019) EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clinical and Translational Radiation oncology 18: 32-38.
12. Dong-Yeop Shin, Im Il Na, Cheol Hyeon Kim et al (2014) EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9: 195-199.
13. Wei-Yuan Chang, Yi-Lin Wu, Po-Lan Su et al (2018) The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. Plos One 13(2): 0192161.
14. Kuilpers CCHJ, Hendriks LEL, Derks JL et al (2018) Association of molecular status and metastatic organs at diagnosis in patients with stage IV non squamous non-small cell lung cncer. Lung cancer 121: 76-81.
15. Tomohiro T, Koichi K, Kensuke N et al (2015) Speccific organ metastase and survival in metastatic non-small cell lung cancer. Molecular and clinical oncology 3: 217-221.
16. Carlos G, Saya J, Brian SF et al (2020) The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget 11(21): 1953-1960.
17. Yuankai S, Joseph Siu-Kie A, Sumitra T et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with Advanced non-small cell lung cancer of adenocarcinoma hiaatology (PIONEER). Journal of Thoracic Oncology 9(2): 154-162.
18. Yue-Lun Zhang, Jin-Qiu Yuan, Kai-Feng Wang et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 7(48): 78985-78993.
19. Can Pi, Chong-Rui Xu, Ming-feng Zhang et al (2018) EGFR mutations in early-stage and advanced-stage lung ademocarcinoma: Analysis based on large-scale data from China. Thoracic Cancer 9: 814-819.
20. Lina Li, Shuimei Luo, Heng Lin et al (2017), Corelation between EGFR mutation status and the incidence of brain metastaes in patients with non-small cell lung cancer. J Thorac Dis 9(8): 2510-2520.
21. Yuya Fujita, Manabu Kinoshita, Tomohiko Ozaki et al (2020) The impact of EGFR mutation status and single brain metastasis on the survival of non-small cell lung cancer patients with brain metastases. Neuro – Oncology Advances 2(1): 1-8.
2. NCCN Guideline Insights (2020) Non-small cell lung cancer. Version 3.2020, feature updates to the NCCN Guidelines.
3. Masaki H, Sun-Jin K, Isaiah JF et al (2014) The molecular biology of lung cancer brain metastasis: An overview of curent comprehensions and future perspectives. J.Med.Invest 61: 241-253.
4. Mao-hua Z, Hong-tao S, Ji-guang X et al (2016) Combining whole-brain radiotherapy with Gefitinib/Erlotinib for brain metastase from non-small cell lung cancer: A meta-analysis. BioMed Research International Volume 2016, Article ID 5807346.
5. Naoto A, Tsuneo S, Kazuhito M et al (2018) Comparison of the efficacies of the first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small cell lung cancer harboring EGFR mutations. BMC cancer 18: 1012.
6. Paz-Ares L, Tan EH, O’Byrne K et al (2017) Afatinib versus gefititnib in patients with EGFR mutation-positive advanced non-small cell lung cancer: overall survival data from the phase IIb LUX-LUNG 7 trial. Annals of Oncology 28: 270-277.
7. Soria JC, Ohe Y, Reungwetwattana T et al (2018) Osimetinib in Untreated EGFR-Mutated Advanced non-small cell lung cancer. The New England Journal of Medicine 378(2): 113-125.
8. Sally CM Lau, Ullas B, Tony SK Mok et al (2019) Dacomitinib in the management of advanced non-small cell lung cancer. Drugs 79(8): 823-831.
9. Fred H, Alex DC, David A et al (2016) EGFR mutation status on brain metastases from non-small cell lung cancer. Lung cancer 96: 101-107.
10. Vijaya RB, Sanyo D’Souza P, Lynette MS et al (2017) Pidermal Growth Factor Receptor mutations status and brain metastases in non-small cell lung cancer. Journal of Global Oncology 3(3): 208-217.
11. Devarati M, Yu-Hui C, Richard L et al (2019) EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clinical and Translational Radiation oncology 18: 32-38.
12. Dong-Yeop Shin, Im Il Na, Cheol Hyeon Kim et al (2014) EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9: 195-199.
13. Wei-Yuan Chang, Yi-Lin Wu, Po-Lan Su et al (2018) The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. Plos One 13(2): 0192161.
14. Kuilpers CCHJ, Hendriks LEL, Derks JL et al (2018) Association of molecular status and metastatic organs at diagnosis in patients with stage IV non squamous non-small cell lung cncer. Lung cancer 121: 76-81.
15. Tomohiro T, Koichi K, Kensuke N et al (2015) Speccific organ metastase and survival in metastatic non-small cell lung cancer. Molecular and clinical oncology 3: 217-221.
16. Carlos G, Saya J, Brian SF et al (2020) The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget 11(21): 1953-1960.
17. Yuankai S, Joseph Siu-Kie A, Sumitra T et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with Advanced non-small cell lung cancer of adenocarcinoma hiaatology (PIONEER). Journal of Thoracic Oncology 9(2): 154-162.
18. Yue-Lun Zhang, Jin-Qiu Yuan, Kai-Feng Wang et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 7(48): 78985-78993.
19. Can Pi, Chong-Rui Xu, Ming-feng Zhang et al (2018) EGFR mutations in early-stage and advanced-stage lung ademocarcinoma: Analysis based on large-scale data from China. Thoracic Cancer 9: 814-819.
20. Lina Li, Shuimei Luo, Heng Lin et al (2017), Corelation between EGFR mutation status and the incidence of brain metastaes in patients with non-small cell lung cancer. J Thorac Dis 9(8): 2510-2520.
21. Yuya Fujita, Manabu Kinoshita, Tomohiko Ozaki et al (2020) The impact of EGFR mutation status and single brain metastasis on the survival of non-small cell lung cancer patients with brain metastases. Neuro – Oncology Advances 2(1): 1-8.
Article Sidebar
Published
Mar 31, 2021
Issue
Section
Articles
How to Cite
LuậnP. V., TiếnN. Đình, & HảiN. M. (2021). Relationship between EGFR mutations and risk of brain metastase in non-small lung cancer patients: The result from a prospective cohort study. Tạp Chí Y Dược lâm sàng 108, 16(1). https://doi.org/10.52389/ydls.v16i1.663